Ionetix leverages its proprietary cyclotron and accelerator expertise to produce a growing portfolio of critical medical isotopes for targeted alpha therapy and diagnostic imaging. For therapeutics, Ionetix is focused on producing high-purity, alpha-emitting therapeutic isotopes, including actinium-225 (Ac-225) and astatine-211 (At-211); the Company ships Ac-225 globally and At-211 in North America. For diagnostics, Ionetix manufactures Positron Emission Tomography (PET) radiopharmaceuticals through its network of FDA-approved sites close to the point of care. These agents are used in imaging for a variety of medical conditions, including cardiology, oncology and neurology. Ionetix is also exploring additional applications for its particle accelerator technology beyond isotope production.